The latest NCCN guidelines for follicular lymphoma introduce several notable changes that could affect how hospitals shape their drug formularies.
Key updates highlight targeted therapies over traditional chemoimmunotherapy
According to the briefing, the backbone of chemoimmunotherapy and anti‑CD20 agents remains in the guideline, but there is a clear shift toward targeted, non‑chemotherapy options. The most prominent addition is a Category 1 recommendation for tafasitamab combined with rituximab and lenalidomide for patients whose disease has relapsed or is refractory after prior anti‑CD20 treatment. Ryan Haumschild, PharmD, MS, MBA, CPEL, emphasized that this endorsement reflects a broader acceptance of antibody‑directed strategies that avoid cytotoxic chemotherapy.
Related: Exploring Non-Invasive Treatments for Erectile Dysfunction
The panel also noted growing inclusion of bispecific antibodies such as epcoritamab as clinical data mature. While these agents are not yet Category 1, their presence signals an evolving preference for therapies that engage immune cells without conventional chemotherapy. Haumschild explained that the guideline’s language around bispecifics is intentionally tentative, allowing institutions to monitor ongoing trial results while preparing for eventual integration once the evidence base solidifies.
Another focus of the updated guideline is risk stratification. They continue to stress the importance of identifying patients who experience disease progression within 24 months (POD24). For that high‑risk group, the guidelines recommend a biopsy to assess for transformation, highlighting the need for early and accurate diagnostics.
Related: 5 amazing vegetarian recipes with the goodness of protein powder
Guideline categories drive formulary review processes
Formulary committees rely heavily on the NCCN’s category designations. The discussion explained that a Category 2A rating or higher typically triggers an institutional review. The review does not merely decide whether to add a drug; it also defines the specific patient populations that would benefit most, aiming for precise, criteria‑driven pathways.
One slightly awkward phrase emerged during the talk: the reviewers said they try to “build precise, criteria‑driven pathways that support faster time to treatment and more consistent, evidence‑based prescribing decisions.” The wording shows the deliberate effort to move beyond anecdotal practice patterns toward reproducible, data‑backed pathways that can be audited across inpatient and outpatient environments.
Related: Migraine Or Headache? Migraine Symptoms, Triggers, Treatments
Hospitals must adapt quickly.
Looking ahead, the next episode will explore how institutions can streamline prior authorization for newer regimens. It will cover operational strategies such as full order sets, thorough documentation packages, and proactive appeal preparation, all aimed at reducing delays and ensuring patients receive the most appropriate therapy without unnecessary hurdles. Ryan Haumschild will also discuss the infrastructure investments needed to support these strategies, including electronic health‑record integrations that automatically flag eligible patients for the newly approved tafasitamab‑rituximab‑lenalidomide combination, thereby embedding guideline compliance into the prescribing workflow.
